BCM
TARS icon

Bayesian Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Bayesian Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,214
Closed -$268K – 867
2025
Q1 		$268K Buy
5,214
+1,100
+27% +$54.4K 0.04% 417
2024
Q4 		$228K Buy
+4,114
New +$187K 0.03% 545
2024
Q1 		– Sell
-15,400
Closed -$312K – 1111
2023
Q4 		$312K Buy
+15,400
New +$257K 0.03% 494

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Bayesian Capital Management's TARS Position: Q2 2025 in Review

Bayesian Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q2 2025, closing a stake of 5,214 shares — an estimated $268K sold.

Bayesian Capital Management first reported a position in TARS in Q4 2023 and held it in 3 quarters. The position peaked at $312K in Q4 2023. 205 funds tracked by Wall St. Rank hold TARS as of Q2 2025.

  • Bayesian Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 5,214 Tarsus Pharmaceuticals shares in Q2 2025, an estimated $268K.
  • Bayesian Capital Management first reported a position in Tarsus Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Bayesian Capital Management's Tarsus Pharmaceuticals position peaked at $312K in Q4 2023.
  • 205 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.